PRESS RELEASE DUBLIN.

Logo-ttp://photos.prnewswire.com/p. The acquisition of Auden Mckenzie makesActavisthe number one supplier of generic pharmaceuticals in theUKand gives the Company the number three position in the supply ofUKpharmaceuticals. The acquisition of Auden Mckenzie can be a strategic combination that makesActavisthe number 1 generic company in theUKand aligns with our strategy to establish a leading position in all of our markets, franchises and therapeutic groups, saidBrent Saunders, CEO and President of Actavis. Auden Mckenzie's knowledge in the commercialization and development of high value, technically demanding formulations in addition to specialized and market opportunities is complementary to and expandsActavis'UKbusiness concentrate, saidRobert Stewart, Executive Vice President Actavis, and President, Generics and Global Operations.Some limitations of our study should be noted. Because patients in the open-restoration group did not go through CT in the third and 4th years after aneurysm fix, and because only about one fourth of patients in the open-repair group underwent CT at 5 years , ascertainment bias probably contributed to the finding of more graft-related complications in the endovascular-fix group. Conversely, because it is not common practice to follow patients for more than 6 to 12 a few months after open repair, the elaborate follow-up protocol for all individuals in the Wish trial during the initial 2 postoperative years may have led to an artificially high rate of early reintervention after open repair. Another limitation of our trial concerns the relatively wide confidence interval for the difference in the primary outcome.